The significant equity issuance at a market cap of only $2 million suggests severe dilution for existing shareholders. Traders should monitor how the market prices this dilution against the potential value of the SAB-142 clinical program, particularly as the company advances its Phase 2b trial for type 1 diabetes.
SABS drugs
SABS drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $3.78entry
- T+1 · 8mo ago −0.79%α +0.95% · $3.75
- T+5 · 8mo ago +1.32%α +3.53% · $3.83
- T+20 · 7mo ago +1.85%α −5.77% · $3.85
- T+60 · 5mo ago +3.17%α −11.17% · $3.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to purchase up to 2.8 million shares at $3.85 per share, with an option for underwriters to purchase up to an additional 3.3 million shares. The company expects to raise approximately $69.7 million in net proceeds (up to $81.7 million if the option is exercised), which will be used primarily to fund clinical development of its lead product candidate SAB-142 for type 1 diabetes.
Key Financial Metrics
Key Facts
- Offering includes 19,324,677 shares of common stock and pre-funded warrants for 2,753,246 shares at $3.85 per share
- Underwriters have a 30-day option to purchase up to 3,311,688 additional shares
- Expected net proceeds of $69.7 million ($81.7 million if option exercised), after underwriting discounts and expenses
- Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes
- Company has a market cap of only $2 million despite raising significant capital
Financial Impact
Approximately $69.7 million in net proceeds ($81.7 million maximum) through issuance of 22.1 million shares (up to 25.4 million with option) and warrants for 2.8 million shares
Risk Factors
- Extreme shareholder dilution from issuing over 22 million new shares
- Low market cap of $2 million indicates limited market confidence despite capital raise
- Clinical-stage biotech with unproven technology and no commercial products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-114730 |
| Document: sabs-ex4_1.htm | 0001193125-26-114730 |
| Document: sabs-20260317.htm | 0001193125-26-114730 |
| Document: sabs-ex5_1.htm | 0001193125-26-114730 |
| Document: sabs-ex99_2.htm | 0001193125-26-114730 |
| Document: sabs-ex99_1.htm | 0001193125-26-114730 |
| Document: 0001193125-26-114730-index-headers.html | 0001193125-26-114730 |
| Document: 0001193125-26-114730-index.html | 0001193125-26-114730 |
| Document: 0001193125-26-114730.txt | 0001193125-26-114730 |
Track record
15 reports on SABS
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers